Use and positioning of fostamatinib in the management of primary chronic immune thrombocytopenia: an Italian expert opinion.

"The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: AL has consulted for and participated on speakers’ bureaus for Amgen, Grifols, Novartis, Sobi. BF received consultancy honoraria from Amgen, Janssen, Momenta, Novartis, and Sobi. VDS received advisory board and speaker fees from Amgen, Grifols, Sobi, and Novartis. SS received consultancy honoraria from Amgen, CSL, Janssen, Novartis, Novo Nordisk, Pfizer, Sobi, and Takeda. NV received advisory board and speaker fees from Amgen, Grifols, and Novartis. FZ received advisory board and speaker fees from Amgen, Argenx, Grifols, Novartis and Sobi; funding for clinical studies from, Amgen, Grifols, Novartis, Sobi. FR received advisory board/speakers’ bureau fees from Amgen, Argenx, and Novartis. Grifols invited the expert panel in an advisory board and facilitated discussion but did not fund or take part to Delphi process, writing or revising the manuscript."

"Funding: The authors received no financial support for the research, authorship, and/or publication of this article."